As the advances in genomic, proteomic and imaging technologies have led to an expansion of our understanding of cancer in general, uro-oncology knowledge and practice is also rapidly evolving. A multi-faceted collaboration among researchers, clinicians, and the industry has emerged. One of the goals of the congress is to discuss these developments in their entirety. In order to address the cutting edge research, translational medicine session will take part in the program. For this reason, the B2B (Bench to Bedside) Renal Cancer Meeting will be held on the first day of the EUA18.